Navigation Links
AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting
Date:5/22/2008

PHILLIPSBURG, N.J., May 22 /PRNewswire-FirstCall/ -- Celldex Therapeutics (a wholly-owned subsidiary of AVANT Immunotherapeutics)(Nasdaq: AVAN) announced today that its lead product candidate, CDX-110, being developed for the treatment of Glioblastoma Multiforme (GBM), will be the subject of an oral presentation at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO). The ASCO meeting will be held at McCormick Place in Chicago from May 30 through June 3, 2008.

The oral presentation, scheduled for Monday, June 2 from 10:00 - 10:15 a.m. CDT in room S406 (Vista Room), will include median survival data from ACTIVATE, a phase IIa clinical trial, and data from ACT II, the extension arm of the study. The presentation will be given by John H. Sampson, MD, PhD, Associate Professor of Neurosurgery at Duke University Medical Center.

On April 16, 2008, Pfizer, Inc. and Celldex entered into an agreement that granted Pfizer an exclusive worldwide license to CDX-110, an investigational vaccine currently in development for the treatment of GBM.

About CDX-110

CDX-110 is designed to induce or enhance the body's immune responses against epidermal growth factor variant III (EGFRvIII) and may lead to destruction of tumor cells that express this variant receptor. A randomized Phase 2 trial is currently enrolling at 24 sites across the United States.

About Glioblastoma Multiforme

GBM is the most common form of primary brain tumor. It is an aggressive tumor with very poor prognosis.(1) There are an estimated 10,000 new cases of GBM annually in the United States, which predominantly affects adults aged 45 to 70. Current GBM treatment options include surgical resection, radiotherapy and chemotherapy.
'/>"/>

SOURCE AVANT Immunotherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing
2. Biopure Announces 2008 Second Quarter Financial Results
3. NeoStem Announces Private Placement Financing to Advance Marketing Campaign; Financing Includes Investment from New England Cryogenic Center
4. Rentschler Biotechnologie Announces Cooperation with Boehringer Ingelheim
5. Still River Systems Announces Operation of the Worlds Highest Magnetic Field Cyclotron
6. Aton Pharma Announces Distribution Partnership in the Asia Pacific Region
7. Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG
8. eResearchTechnology Announces Resignation of its CFO
9. Biodel Inc. Announces Appointment of Alan Krasner, M.D. as Chief Medical Officer
10. Oncolytics Biotech Inc. Announces Issuance of 27th U.S. Patent
11. Amarin Announces Financial Results for Fourth Quarter and Full Year 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014 ... two institutes from the National Institutes of Health (NIH) ... safer, more effective treatments to patients on a faster ... Advancing Translational Sciences (NCATS) and the National Eye Institute ...
(Date:1/14/2014)... Toronto, Canada (PRWEB) January 14, 2014 ... and its motives and methods in product development and ... of the industry. This mistrust, fueled by concerns about ... further fed by reports of spectacular fines to the ...
(Date:1/14/2014)... 2014 Global Record Systems, LLC, ... technology solutions for patients, physicians, the biopharmaceutical industry, ... today the signing of a three-year Research Collaboration ... Administration (FDA). This initiative is designed to ...
(Date:1/14/2014)... and Cardiff, UK (PRWEB) January 13, 2014 ... development leader with more than 20 years in the ... optics and photonics . Hainsey will serve as the ... to have Dr. Hainsey join SPIE as our Technology ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... Thera, Inc.,announced today that the United States Patent ... "Protein-fragment Complementation,Assays (PCA) in whole animals: applications to ... gene therapy." This is the,twelfth patent issued for ... a method for detecting protein-protein,interactions in living cells ...
... Dec. 12 Genaera,Corporation (Nasdaq: GENR ) today ... Genaera, is scheduled to present at the 2007,RBC Capital ... Capital Markets, panel discussion of diabetes and obesity, entitled,"The ... place in,New York on Thursday, December 13 at 10:00 ...
... (OTC,Bulletin Board: BMOD) ( http://www.biomoda.com ) of Albuquerque, ... (New Mexico Tech at, http://www.nmt.edu ) reached an ... development of specialized image recognition technology as,part of ... early,detection of lung cancer., New Mexico Tech, ...
Cached Biology Technology:Odyssey Thera Granted U.S. Patent for Animal Imaging 2Biomoda Announces Collaborative Agreement With New Mexico Tech 2
(Date:4/17/2014)... eight hundred births, Down syndrome - or trisomy 21 ... disability. It results from a chromosomal abnormality where cells ... 21 (1% of the human genome). A study conducted ... of Genetic Medicine and Development at the University of ... , shed light on how the extra chromosome 21 ...
(Date:4/17/2014)... Singh Thursday as a "Champion of Change" for ... in the residential, commercial and industrial sectors. , ... and Computer Engineering and director of Clemson,s Center ... leading the charge across the country to create ... driving policy changes at the local level to ...
(Date:4/17/2014)... implicated in many serious conditions such as heart disease, ... for drug therapies. Unfortunately, there is still much scientists ... provides fresh and unexpected insight into the structure of ... β-subunit molecules - which are responsible for ,fine-tuning, the ... the most recent edition of the Journal of ...
Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3White House honors Clemson professor as 'Champion of Change' for solar deployment 2Structure of sodium channels different than previously believed 2
... , ,Mathematical models continue to play a major ... and control of malaria, a life-threatening parasitic disease ... Although existing models have advanced our understanding of ... new challenges., The National Institute for Mathematical and ...
... JOLLA, CA January 18, 2011 Using chemical compounds ... clever application of ultraviolet light, a Scripps Research Institute team ... to test for biomedical potential. Already, one of the compounds ... and fighting inflammation. With the report of their ...
... how the hormones progesterone and estrogen interact to increase ... a novel finding that may explain why postmenopausal women ... at increased risk of breast cancer. The discovery ... the increased production of the protein amphiregulin, which binds ...
Cached Biology News:Malaria modeling and control focus of workshop 2Scripps Research team creates new synthetic compound with HIV-fighting promise 2Scripps Research team creates new synthetic compound with HIV-fighting promise 3Researchers unlock how progesterone increases breast cancer risk 2